Q-omics provides the consensus-scored SOX4 profile across patient tissues and cancer cell-line models. SOX4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SOX4 is differentially expressed in 17, with the highest sampling consensus in STAD. Additionally, SOX4 RNA expression shows 19,188 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, STAD, and UVM as cancer lineages where SOX4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOX4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOX4 survival associations across molecular data types. SOX4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOX4 RNA expression–survival associations across cancer types. High SOX4 expression shows unfavorable associations in ACC, LIHC, SKCM and SARC, but favorable associations in HNSC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SOX4 RNA expression.
This table summarizes SOX4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SOX4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOX4 shows higher tumor expression in STAD, BLCA, HNSC, COAD, THCA and LUAD. The STAD box plot shows higher SOX4 RNA expression in tumor versus normal tissue (log2 FC = +2.486, t-test p < 0.001).
This table shows molecular features associated with SOX4 in patient tissues and cancer cell lines. In patient samples, SOX4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SOX4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
